[go: up one dir, main page]

TN2013000508A1 - Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer - Google Patents

Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer

Info

Publication number
TN2013000508A1
TN2013000508A1 TNP2013000508A TN2013000508A TN2013000508A1 TN 2013000508 A1 TN2013000508 A1 TN 2013000508A1 TN P2013000508 A TNP2013000508 A TN P2013000508A TN 2013000508 A TN2013000508 A TN 2013000508A TN 2013000508 A1 TN2013000508 A1 TN 2013000508A1
Authority
TN
Tunisia
Prior art keywords
inhibitor
cdk4
cancer
treatment
combination therapy
Prior art date
Application number
TNP2013000508A
Other languages
English (en)
Inventor
Sunkyu Kim
Shivang Doshi
Kristy Haas
Steven Kovats
Alan Xizhong Huang
Yan Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000508(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000508A1 publication Critical patent/TN2013000508A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2013000508A 2011-07-01 2013-12-06 Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer TN2013000508A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503642P 2011-07-01 2011-07-01
PCT/US2012/045199 WO2013006532A1 (fr) 2011-07-01 2012-07-02 Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer

Publications (1)

Publication Number Publication Date
TN2013000508A1 true TN2013000508A1 (en) 2015-03-30

Family

ID=46513871

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000508A TN2013000508A1 (en) 2011-07-01 2013-12-06 Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer

Country Status (23)

Country Link
US (2) US9271988B2 (fr)
EP (1) EP2726074B1 (fr)
JP (2) JP5832647B2 (fr)
KR (1) KR20140040770A (fr)
CN (1) CN103635189B (fr)
AU (3) AU2012279117A1 (fr)
BR (1) BR112013033940A2 (fr)
CA (1) CA2840754A1 (fr)
CL (1) CL2013003805A1 (fr)
CO (1) CO6842016A2 (fr)
EA (1) EA030465B1 (fr)
ES (1) ES2676180T3 (fr)
GT (1) GT201300320A (fr)
IL (1) IL229876B (fr)
MA (1) MA35210B1 (fr)
MX (1) MX359406B (fr)
MY (1) MY161237A (fr)
PE (1) PE20141381A1 (fr)
PH (1) PH12013502697A1 (fr)
TN (1) TN2013000508A1 (fr)
UA (1) UA114178C2 (fr)
WO (1) WO2013006532A1 (fr)
ZA (1) ZA201309241B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088986A1 (fr) 2008-01-04 2009-07-16 Intellikine, Inc. Entités chimiques, compositions et procédés
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
UA114178C2 (uk) * 2011-07-01 2017-05-10 Новартіс Аг Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку
RU2014143232A (ru) * 2012-03-30 2016-05-27 Новартис Аг Соединения для применения в лечении нейробластомы, саркомы юинга или рабдомиосаркомы
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2880764C (fr) 2012-08-03 2022-08-30 Foundation Medicine, Inc. Papillomavirus humain en tant que predicteur du pronostic du cancer
SMT201800561T1 (it) 2012-11-01 2018-11-09 Infinity Pharmaceuticals Inc Trattamento di cancri usando modulatori di isoforme di pi3 chinasi
EP2742940B1 (fr) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Sel de fumarate de (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane destinés à être administrés une fois par jour, deux fois par jour ou trois fois par jour
SI2968290T1 (sl) 2013-03-15 2020-02-28 G1 Therapeutics, Inc., Prehodna zaščita normalnih celic med kemoterapijo
CA3152117A1 (fr) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Agents antineoplasiques et antiproliferatifs hautement actifs
MX384403B (es) * 2013-08-14 2025-03-14 Novartis Ag Terapia de combinación para el tratamiento del cáncer.
WO2015160986A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US20150297608A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents
WO2016040848A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6
WO2016040858A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
MA42295B1 (fr) 2015-07-02 2020-02-28 Hoffmann La Roche Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
EP3340986A1 (fr) 2015-08-28 2018-07-04 Novartis AG Combinaison pharmaceutique comprenant l'inhibiteur de pi3k alpelisib et l'inhibiteur de cdk4/6 ribociclib et son utilisation dans le traitement/la prévention du cancer
US10690673B2 (en) 2016-03-29 2020-06-23 Mayo Foundation For Medical Education And Research Method of treating cancer metastasis by CDK 4/6 inhibitors
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
WO2018017410A1 (fr) 2016-07-22 2018-01-25 Eli Lilly And Company Polythérapie à base d'abemaciclib et d'un inhibiteur double de kinase pi3 /mtor, destinée à être utilisée dans le traitement du cancer du sein
WO2018081211A1 (fr) * 2016-10-26 2018-05-03 Li George Y 7-cyclopentyl-n,n-diméthyl-2-((5- (pipérazin-1-yl)pyridin-2-yl)amino)-7h- pyrrolo[2,3-d]pyrimidine-6-carboxamide deutéré
EP3548030A4 (fr) 2016-12-05 2020-08-12 G1 Therapeutics, Inc. Préservation de la réponse immunitaire lors de régimes chimiothérapeutiques
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
MX2020007312A (es) 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.
JP2021517119A (ja) * 2018-03-05 2021-07-15 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン 腫瘍溶解性アデノウイルスとｃｄｋ４／６阻害剤との組み合わせによる腫瘍の処置
CN111184863B (zh) * 2018-11-15 2023-06-16 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
KR102861622B1 (ko) * 2021-07-06 2025-09-18 국립암센터 Cdk4/6 억제제 및 삼환계 항우울제를 포함하는 암의 예방 또는 치료를 위한 약학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1575940B1 (fr) 2002-11-21 2011-10-05 Novartis AG Pyrimidines 2,4,6-trisubstitutees utilisees comme inhibiteurs de phosphotidylinositol (pi) 3-kinase et leur utilisation dans le traitement du cancer
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
CA2714177A1 (fr) 2008-02-06 2009-08-13 Novartis Ag Composes heterocycliques
KR101353857B1 (ko) * 2008-08-22 2014-01-21 노파르티스 아게 Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
EP3040333B1 (fr) 2010-10-01 2018-09-12 Novartis AG Formes crystallines de 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4-trifluoromethylpyridin-2-amine, un inhibiteur de pik3
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
UA114178C2 (uk) * 2011-07-01 2017-05-10 Новартіс Аг Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку
AU2013352406A1 (en) * 2012-11-28 2015-06-04 Novartis Ag Combination therapy

Also Published As

Publication number Publication date
CN103635189B (zh) 2016-05-04
ES2676180T3 (es) 2018-07-17
US20160136171A1 (en) 2016-05-19
PH12013502697A1 (en) 2014-02-10
KR20140040770A (ko) 2014-04-03
MA35210B1 (fr) 2014-06-02
MY161237A (en) 2017-04-14
PE20141381A1 (es) 2014-10-21
ZA201309241B (en) 2014-08-27
MX2013015370A (es) 2014-02-11
EA030465B1 (ru) 2018-08-31
IL229876B (en) 2018-10-31
EP2726074A1 (fr) 2014-05-07
CA2840754A1 (fr) 2013-01-10
CN103635189A (zh) 2014-03-12
JP5832647B2 (ja) 2015-12-16
UA114178C2 (uk) 2017-05-10
AU2012279117A1 (en) 2014-01-09
AU2016202213A1 (en) 2016-05-05
AU2017232162A1 (en) 2017-10-12
JP2016027043A (ja) 2016-02-18
EA201490194A1 (ru) 2014-04-30
AU2017232162B2 (en) 2019-03-07
GT201300320A (es) 2016-03-01
US10010552B2 (en) 2018-07-03
US9271988B2 (en) 2016-03-01
CL2013003805A1 (es) 2014-08-08
MX359406B (es) 2018-09-27
JP2014518279A (ja) 2014-07-28
WO2013006532A1 (fr) 2013-01-10
EP2726074B1 (fr) 2018-04-04
US20140107114A1 (en) 2014-04-17
BR112013033940A2 (pt) 2017-02-14
CO6842016A2 (es) 2014-01-20

Similar Documents

Publication Publication Date Title
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
NZ702244A (en) Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
PL2544680T3 (pl) Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
ZA201202384B (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
MX346379B (es) Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer.
IL238400A0 (en) Triazolopyrazines as brd4 inhibitors for use in cancer therapy
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
IL232353B (en) An inhibitor of the nedd8 mecatenase and a hypomethylated agent for use in cancer therapy
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2013015357A (es) Terapia de combinacion.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
IN2015KN00676A (fr)
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
UA70775U (ru) Способ лечения менингококцемии у детей
AU2012904722A0 (en) Agents for cancer therapy or prophylaxis and uses therefor
AU2012900259A0 (en) Agents for use in cancer therapy